subsequ
determin
blind
set
presenc
lgv
select
group
patient
clinic
spectrum
epidemiolog
describ
elsewher
accord
c
trachomatisposit
rectal
swab
chlamydia
collect
transport
kit
quelab
commerci
avail
pcr
coba
amplicor
hoffmanla
roch
ltd
use
refer
standard
techniqu
type
c
trachomati
serovar
pcrbase
rflp
gene
sequenc
variabl
segment
gene
dna
isol
rectal
swab
specimen
standard
isopropanol
dna
isol
method
identifi
men
lgvposit
sampl
also
posit
taqman
rotorgen
assay
also
identifi
addit
lgv
infect
initi
type
retest
singlestrain
infect
serovar
e
pcrbase
rflp
analysi
sequenc
discrep
like
due
doubl
infect
case
result
preferenti
amplif
strain
pcr
pcrbase
sequenc
method
taqman
rotorgen
assay
lgv
strain
amplifi
whether
outbreak
partial
technic
driven
must
assess
futur
retrospect
investig
presenc
lgv
infect
men
sex
men
presenc
strain
past
sinc
present
lgv
infect
investig
editor
less
year
identif
sever
acut
respiratori
syndrom
coronaviru
sarscov
independ
laboratori
report
protect
sarscov
challeng
anim
model
use
dna
vaccin
recombin
form
modifi
vaccinia
ankara
parainfluenza
viru
encod
spike
gene
protect
efficaci
encourag
provid
proof
sarscov
vaccin
feasibl
howev
vaccin
base
technolog
licens
human
use
recommend
licens
like
take
mani
year
develop
inactiv
viru
vaccin
induc
neutral
antibodi
protect
sarscov
challeng
vaccin
produc
describ
elsewher
briefli
sarscov
strain
fra
genbank
access
grown
vero
cell
inactiv
bpl
complet
inactiv
confirm
consecut
passag
vero
cell
inactiv
viru
purifi
column
chromatographi
follow
sucros
gradient
centrifug
fraction
contain
viru
dialyz
phosphatebuff
salin
ph
total
protein
content
determin
use
micro
bca
protein
assay
kit
pierc
biotechnolog
rockford
il
usa
immunogen
vaccin
test
immun
balbc
mice
week
inactiv
viru
combin
adjuv
oil
squaleneinwat
emuls
approv
human
use
europ
influenza
vaccin
ten
day
third
immun
serum
sampl
test
presenc
sarscov
spike
proteinspecif
antibodi
use
enzymelink
immunosorb
assay
high
titer
antisarscov
spike
immunoglobulin
ig
g
antibodi
detect
igg
subclass
determin
indic
predomin
immun
respons
similar
observ
balbc
mice
vaccin
uvinactiv
sarscov
plu
alum
efficaci
inactiv
viru
vaccin
also
assess
balbc
mous
model
sarscov
infect
anim
studi
approv
nation
institut
health
anim
care
use
committe
conduct
anim
biosafeti
level
facil
sarscov
replic
respiratori
tract
balbc
mice
follow
intranas
infect
tissu
cultur
infecti
dose
tcid
viru
gener
viru
titer
peak
within
day
infect
clear
within
day
balbc
mice
immun
week
bplinactiv
sar
viru
without
adjuv
mice
also
immun
differ
control
prepar
phosphatebuff
salin
adjuv
alon
bpl
inactiv
influenza
viru
vaccin
without
serum
sampl
collect
week
dose
assay
abil
neutral
sarscov
vaccin
dose
sarscov
neutral
antibodi
detect
group
mice
immun
bplinactiv
sar
viru
vaccin
plu
adjuv
two
week
third
dose
bplinactiv
sar
viru
vaccin
without
induc
neutral
titer
adjuv
vaccin
elicit
neutral
titer
tabl
mice
challeng
intranas
point
tcid
sarscov
urbani
strain
genbank
access
nasal
turbin
lung
tissu
analyz
infecti
viru
day
later
tabl
sarscov
titer
mice
control
group
tcid
virusg
lung
tissu
tcid
virusg
nasal
turbin
tissu
complet
protect
viru
replic
observ
mice
receiv
adjuv
sarscov
vaccin
immun
nonadjuv
vaccin
result
complet
protect
upper
respiratori
tract
signific
reduct
viral
titer
lower
respiratori
tract
compar
control
group
incomplet
protect
group
attribut
singl
anim
contain
detect
infecti
viru
lung
acceler
enhanc
viru
replic
diseas
immun
person
concern
develop
vaccin
may
particularli
true
sarscov
vaccin
sinc
advers
effect
report
one
anim
coronaviru
vaccin
felin
infecti
periton
viru
addit
vitro
experi
perform
pseudotyp
lentivirus
express
spike
glycoprotein
deriv
sarslik
viru
isol
civet
experi
presenc
antibodi
neutral
human
isol
sarscov
demonstr
enhanc
entri
renal
epitheli
cell
studi
find
enhanc
viru
replic
respiratori
tract
vaccin
mice
upon
sarscov
challeng
howev
sinc
mice
model
sarscov
infect
diseas
issu
diseas
enhanc
care
evalu
appropri
anim
model
phenomenon
demonstr
becom
avail
summari
inactiv
sarscov
vaccin
produc
technolog
safeti
record
establish
immun
hundr
million
person
protect
mice
challeng
sarscov
vaccin
adjuv
elicit
neutral
antibodi
titer
dose
conclud
vaccin
describ
desir
properti
data
support
develop
plan
clinic
trial
